What is Preveceutical's primary product?

The deck does not highlight a single flagship product. Instead, it describes a 'signature portfolio of disease preventive health products and services' (Slide 3). Slide 12 shows mockups of essential oil-style bottles, but the overall strategy focuses on branding the entire preventive health sector rather than a specific medical or nutritional formulation.

How does Preveceutical plan to generate revenue?

According to the Business Model Canvas on Slide 18, revenue is generated through four main streams: Royalties, Monetizing Trademarks, Licensing, and direct Product sales. The strategy emphasizes 'Strong Sector Branding' and 'Unified Message' as the primary value propositions to drive these streams.

What is the company's exit or growth strategy?

The company is pursuing a public listing strategy. Slide 22 explicitly states a goal to 'Go public with triple CSE, OTCQX & Frankfurt' listings. Additionally, the strategy includes the acquisition of other preventive wellness products, pharmaceuticals, equipment, and practitioner programs to expand the brand's reach.

Who are the key people leading the company?

The leadership is led by Stephen Van Deventer (Chairman, CEO, Director) and Kimberley Cole (President, CFO, Director). Their backgrounds are primarily in corporate finance, restructuring, and venture capital, rather than medical research or pharmaceutical science (Slide 19).

What market gap is Preveceutical trying to fill?

The deck argues that while there are brand leaders like GNC and Herbalife, there is 'no Apple of the Preventive Sector' (Slide 11). Preveceutical intends to fill this void by creating a unified brand that spans across medicine, nutraceuticals, fitness, and lifestyle sectors.

Preveceutical Medical Inc. Pitch Deck (2021) Breakdown

See all 23 slides of the Preveceutical Medical Inc. pitch deck, with a slide-by-slide teardown of what the deck does well and where it falls short.

Preveceutical presents a 23-slide deck that prioritizes brand identity within the preventive health market. The company argues that while the wellness sector is growing—projected to reach $279B by 2021 as shown on slide 6—it lacks a definitive 'Apple-like' leader. Their strategy involves monetizing trademarks, royalties, and licensing across five pillars: practitioner care, medical compounds, nutraceuticals, fitness, and lifestyle. The deck is notable for its focus on corporate structure and advisory expertise rather than specific product formulations or clinical data. It concludes with a cle…

Key takeaways

The company identifies a massive market opportunity, citing a growth from $56.4B in 2011 to a projected $279B in 2021 (Slide 6).
Preveceutical positions itself as the first to 'invent the name' for a sector that already existed, aiming to be the dominant brand leader (Slide 17).
The business model is diversified across five key areas: Practitioner Care, Medical Compounds, Nutraceuticals, Fitness, and Lifestyle (Slide 14).
The company utilizes a Business Model Canvas to illustrate revenue streams including royalties, trademark monetization, licensing, and products (Slide 18).
The Board of Directors and Advisory Board are heavily weighted toward corporate finance, restructuring, and public listing expertise (Slides 19-21).
A core component of the corporate strategy is a 'triple' public listing on the CSE, OTCQX, and Frankfurt exchanges (Slide 22).
The deck lacks a specific investment ask, use of funds breakdown, or detailed financial historicals.
The strategy relies heavily on branding and 'sector solidification' rather than proprietary scientific breakthroughs or clinical trial data (Slide 18).

Preveceutical Pitch Deck Analysis

Preveceutical's pitch deck is a study in brand-centric market positioning. Rather than leading with a scientific breakthrough or a specific product, the company leads with the concept of 'Preventive Health' as an unclaimed brand territory. The deck is structured to convince investors that the wellness market is ripe for a consolidated leader and that Preveceutical has the corporate infrastructure to fill that role.

Slides 1-5: The Philosophy of Prevention

The deck opens with a high-level introduction to the concept of preventive healthcare. Slide 3 quotes Desiderius Erasmus, "Prevention is better than cure," establishing the company's ideological foundation. Slide 4 and 5 use lifestyle imagery to define preventive care as a 'phenomenon' and claim that wellness products are the economy's next 'trillion-dollar industry.' At this stage, the deck is selling a macro-trend rather than a specific business entity.

Slides 6-9: Market Validation and Growth

Slide 6 provides specific market figures, showing a growth trajectory from $56.4B in 2011 to $165.62B in 2014, with a projection of $279B by 2021. This is followed by Slide 7, which lists 'Brand Leaders' such as USANA Health Sciences ($1.62B Market Cap) and Herbalife Ltd. ($5.06B Market Cap). By showing the high market caps of existing players, the deck attempts to establish the valuation ceiling for successful companies in this space. Slide 9 adds a social dimension, showing average life expectancy increasing from 67 in 1960 to 82 in 2015, attributing this to better health awareness.

Slides 10-13: The Branding Opportunity

Slide 10 categorizes preventive health into five sectors: Practitioner Care, Medicine, Nutraceuticals, Fitness, and Lifestyle. The core thesis of the deck is presented on Slide 11: "But, there is no Apple of the Preventive Sector." The company argues that no major brand has dominated the space. Slide 12 and 13 introduce the Preveceutical brand identity, showing the logo on various digital devices and outdoor advertisements. This section makes it clear that the company views itself primarily as a branding and marketing powerhouse.

Slides 14-17: Defining the 'Preveceutical' Category

Slide 14 maps the brand across the five previously mentioned sectors, suggesting a global reach. Slide 16 attempts to differentiate the term 'Preveceutical' from 'Nutraceutical.' It notes that the word 'Nutraceutical' was invented in 1989 and focuses on ingestible products, whereas 'Preveceutical' (invented in 2015) encompasses early detection, chronic disease management, and advanced technologies. Slide 17 reinforces this by stating, "The sector was already there. We invented the name for it." This is a bold claim that positions the company as a category creator.

Slide 18: The Business Model Canvas

This slide provides the most functional detail in the deck. It lists key partners like pharmacies and natural food stores, and key activities like royalties and branding. The 'Cost Structure' is described simply as 'Minimal' and 'Marketing,' which is a vague characterization for a startup. The 'Revenue Streams'—Royalties, Monetizing Trademark, Licensing, and Products—suggest a capital-light model focused on intellectual property rather than heavy manufacturing.

Slides 19-21: The Team and Advisory Board

The leadership team presented on Slide 19 is heavily focused on finance. Stephen Van Deventer and Kimberley Cole both have backgrounds as 'Public Listing Advisors' and 'Merchant Bankers.' This theme continues into the Advisory Board (Slides 20-21), which includes experts in corporate finance, M&A, and startup consulting. Notably, there is a lack of medical doctors or PhD scientists on the primary board slides, which is unusual for a company with 'Medical Inc.' in its name (as seen on Slide 22).

Slide 22: Corporate Strategy and Contact

The final content slide outlines a four-part strategy: (A) Revenue through trademarks and licensing, (B) Acquisitions of wellness products and pharma, (C) Branding and marketing, and (D) A public listing on the CSE, OTCQX, and Frankfurt exchanges. This confirms that the company's primary goal is a public market exit. The contact slide (Slide 23) identifies the company as 'Preveceutical Medical Inc.' based in British Columbia, Canada.

What Works in This Deck

Clear Market Thesis: The argument that the preventive health sector lacks a 'unified brand' is a compelling hook for investors looking for a platform play. · Visual Consistency: The deck uses a consistent color palette and professional imagery, which supports the company's focus on branding. · Defined Revenue Streams: The Business Model Canvas clearly outlines how the company intends to make money beyond just selling physical products. · Ambitious Exit Strategy: The specific mention of a 'triple' public listing gives investors a clear understanding of the intended liquidity path.

What Is Missing from This Deck

Product Specifics: There is no information on what the 'signature portfolio' actually contains. Are these patented drugs, supplements, or software tools? · Scientific Validation: For a company operating in the medical and nutraceutical space, the absence of clinical data, white papers, or scientific advisors is a significant red flag. · Financials: The deck contains no historical revenue, burn rate, or future financial projections. The 'Minimal' cost structure on Slide 18 lacks credibility without supporting data. · The Ask: There is no slide indicating how much capital the company is seeking to raise or how that capital will be deployed. · Competitive Analysis: While it mentions 'Brand Leaders' on Slide 7, it does not explain how Preveceutical will compete with these multi-billion dollar incumbents.

Founder Takeaways

Sell the Category, Not Just the Product: Preveceutical does an excellent job of framing a market opportunity as a 'gap in branding.' Founders building in fragmented industries can learn from how this deck positions the company as a potential 'category king.'

Align the Team with the Strategy: The team's background in public listings perfectly aligns with the stated goal of a triple exchange listing. If your goal is an IPO, your board should reflect that expertise.

Don't Forget the 'How': While branding is important, investors in the health and medical space need to see the underlying 'moat.' Whether it is IP, proprietary formulations, or exclusive distribution rights, the 'how' is just as important as the 'what.' This deck leans too heavily on the 'what' (branding) without explaining the 'how' (the science or product efficacy).

Be Specific About the Ask: A pitch deck is a tool for a transaction. Omitting the funding amount and the use of proceeds makes the deck feel like a general corporate presentation rather than an active fundraising document.

Frequently asked questions

What is Preveceutical's primary product?: The deck does not highlight a single flagship product. Instead, it describes a 'signature portfolio of disease preventive health products and services' (Slide 3). Slide 12 shows mockups of essential oil-style bottles, but the overall strategy focuses on branding the entire preventive health sector rather than a specific medical or nutritional formulation.
How does Preveceutical plan to generate revenue?: According to the Business Model Canvas on Slide 18, revenue is generated through four main streams: Royalties, Monetizing Trademarks, Licensing, and direct Product sales. The strategy emphasizes 'Strong Sector Branding' and 'Unified Message' as the primary value propositions to drive these streams.
What is the company's exit or growth strategy?: The company is pursuing a public listing strategy. Slide 22 explicitly states a goal to 'Go public with triple CSE, OTCQX & Frankfurt' listings. Additionally, the strategy includes the acquisition of other preventive wellness products, pharmaceuticals, equipment, and practitioner programs to expand the brand's reach.
Who are the key people leading the company?: The leadership is led by Stephen Van Deventer (Chairman, CEO, Director) and Kimberley Cole (President, CFO, Director). Their backgrounds are primarily in corporate finance, restructuring, and venture capital, rather than medical research or pharmaceutical science (Slide 19).
What market gap is Preveceutical trying to fill?: The deck argues that while there are brand leaders like GNC and Herbalife, there is 'no Apple of the Preventive Sector' (Slide 11). Preveceutical intends to fill this void by creating a unified brand that spans across medicine, nutraceuticals, fitness, and lifestyle sectors.

Cover slide of the Preveceutical Medical Inc. pitch deck — Pre-Public / Growth 2021 — Preveceutical Medical Inc. pitch deck, slide 1 (2021)

Preveceutical Medical Inc. pitch deck: the facts

Company: Preveceutical Medical Inc.
Year: Not stated…
Stage: Pre-Public / Growth
Slides: 23
Sector: Preventive Health / Nutraceuticals
Deck type: Investor Pitch Deck
Outcome: Not stated
Headquarters: British Columbia, Canada

Preveceutical Medical Inc. pitch deck PDF

The full Preveceutical Medical Inc. deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the PreveCeutical Medical Inc. pitch deck was used for

This deck is a PreveCeutical Medical Inc. pitch deck / business plan prepared by Concord Business Plans in advance of a planned public listing on the TSX Venture Exchange, with projections extending through 2021. The deck positions PreveCeutical as a preventive health and nutraceutical company aiming to lead the trillion‑dollar preventive healthcare market, emphasizing aggressive branding and a multi‑channel business model. It describes the company as focusing on branding a signature portfolio of disease‑preventive health products and services globally, and provides corporate details such as its incorporation in British Columbia and contact information in West Vancouver. The stage indicated around the time of the deck is pre‑public / growth, focused on preparing for a going‑public transaction rather than a specific named private round.

Business model: Health sciences company developing options for preventive and curative therapies utilizing organic and nature-identical products, including licensing, branding, and marketing of nutraceutical and wellness products.

Headquarters: West Vancouver, British Columbia, Canada.
Industry: Health sciences / biotechnology / nutraceuticals.

Round: Pre‑public / going‑public preparation for TSX Venture listing, as indicated by the Slideshare description that the deck was prepared before the company went public on the TSXv exchange.

Year: 2016 or earlier, as the Slideshare upload date is January 2016 and the deck includes projections through 2021, indicating a pre‑2016 or circa‑2015 fundraising and listing preparation period.

What happened after the PreveCeutical Medical Inc. deck

Following the pre‑public pitch deck that outlined its preventive health and nutraceutical strategy and indicated plans for a TSX Venture listing, PreveCeutical became a publicly traded health sciences company and developed a pipeline of cannabinoid Sol‑Gel, peptide, gene therapy, and other preventive and therapeutic programs, as evidenced by subsequent public profiles and news releases.

PreveCeutical proceeded to become a publicly traded company, with stock and company profiles available on financial data
The company established and publicized multiple research and development programs, including cannabinoid Sol‑Gel nose‑to
PreveCeutical has continued to communicate with investors via news releases and corporate updates, indicating ongoing op

What the PreveCeutical Medical Inc. deck got right

Compelling preventive healthcare market positioning. The deck clearly positions PreveCeutical in the large and growing preventive healthcare market, describing an ambition to brand a signature portfolio of disease‑preventive health products and services globally and referencing the trillion‑dollar market size, which can resonate with investors seeking exposure to macro health trends.
Clear stated path toward TSX Venture public listing. It explicitly states that the deck was prepared in advance of a TSX Venture listing, signaling a concrete capital markets pathway and giving investors clarity that the company is targeting a public listing rather than only private capital.
Strong corporate and professional disclosure. The deck includes detailed corporate information such as incorporation in British Columbia, West Vancouver principal address, legal counsel (Nox Law Corporation), and auditors (Buckley, Dodds Parker LLP), which enhances credibility and facilitates investor due diligence.
Coherent multi‑channel branding strategy aligned with later business focus. The business plan emphasizes a multi‑channel model and strong branding strategy for preventive health products and services, which aligns with the company’s later evolution into licensing, branding, and marketing of nutraceutical and wellness products.
Transparent contact and communication details. Contact details for key individuals (including Stephen and Kimberley) and the company website are included, which provides transparency and accessibility for potential investors reviewing the deck.

What could have been stronger

No disclosed target raise amount or valuation in public materials. Publicly available information around the deck and its Slideshare listing does not disclose a specific fundraising amount, valuation, or clear use‑of‑proceeds breakdown for the pre‑public financing it supported, leaving investors without key capital‑formation details.
Limited externally visible traction evidence at deck time. While the deck emphasizes becoming a leader in the preventive healthcare market and includes corporate details and branding strategy, the publicly visible description does not reference concrete historical traction metrics (such as revenue, customer numbers, or signed distribution agreements) at the time of the deck.
Unclear linkage between deck and a specific disclosed financing round. The deck frames an ambition to list on the TSX Venture Exchange but external public profiles do not clearly link a specific disclosed private financing round to this deck, making it harder for investors to tie the narrative to an identifiable financing event.

How an investor would read this deck

What draws attention

Evidence that the company did proceed to public trading and continues to operate, as indicated by current company website, stock profiles, and news releases, shows that the pre‑public strategy in the deck led to a listed entity, which is a key de‑risking milestone for investors evaluating this deck
The company’s later R&D pipeline in cannabinoid Sol‑Gel delivery, non‑addictive analgesic peptides, dual gene therapy, and peptide oncology programs demonstrates that the preventive health positioning in the deck evolved into specific health sciences programs, which is relevant for assessing whether
Corporate information in the deck (incorporation in British Columbia, legal counsel, auditors, and West Vancouver address) can be cross‑checked against later filings and profiles listing Vancouver and West Vancouver addresses, helping investors verify continuity and corporate legitimacy.

Risks that stand out

A significant portion of the company’s value proposition relates to early‑stage research programs (such as gene therapy and novel peptide therapeutics), which inherently carry scientific, regulatory, and clinical development risk beyond traditional nutraceutical branding.
The lack of publicly disclosed data tying a specific private placement or financing round to this deck, including exact raise size and investor roster, introduces uncertainty for investors analyzing the historical effectiveness of the deck and the pricing at which capital was raised.
Transitioning from a nutraceutical‑oriented branding and wellness model to a broader health sciences and biotechnology focus, as described in later materials, can increase capital intensity and time to commercialization, affecting the risk‑return profile versus what some preventive health investors

Questions this deck invites

What private placements or financings, if any, were completed in direct connection with the TSX Venture pre‑public process described in the deck, and what were the terms (amounts, valuations, investor types)?
How did the business mix between nutraceutical branding and more advanced health sciences R&D (such as Sol‑Gel delivery and gene therapy programs) evolve after the period covered by the deck, and how did this affect capital requirements and
What regulatory pathways (nutritional supplement versus drug approval) did PreveCeutical pursue for its key products after the deck period, and how did those choices compare to the regulatory assumptions, if any, implied in the deck’s proje
How did the company’s actual revenue, partnership development, and R&D progress from the time of the deck through its subsequent public reporting compare to the projections and milestones outlined in the original deck’s forecasts to 2021?
What governance, board composition, and audit arrangements were in place during and after the pre‑public financing phase (referencing the legal counsel and auditors named in the deck), and how have they changed as reflected in later public

What founders can take from the PreveCeutical Medical Inc. deck

A pitch deck built around a broad preventive health and nutraceutical thesis can later evolve into a more defined health sciences R&D pipeline, illustrating how early branding‑focused narratives may precede a shift into deeper therapeutic development.
Preparing a deck specifically for a planned TSX Venture listing, as noted in the Slideshare description, shows how companies can tailor investor materials to support a going‑public strategy rather than only traditional private rounds.
Including detailed corporate information such as incorporation jurisdiction, principal address, legal counsel, and auditors in a deck can be valuable for investors, as these details can later be cross‑checked against public filings and company profiles.
Positioning in a large, rapidly growing market (like the trillion‑dollar preventive healthcare sector) can be compelling, but investors will still look for concrete product pipelines and R&D programs, as seen in PreveCeutical’s later emphasis on specific Sol‑Gel, peptide, and gene therapy programs.
When projections in a deck extend several years into the future (in this case through 2021), subsequent public disclosures provide a lens for comparing planned versus actual progress, which is critical for assessing management’s forecasting credibility.

PreveCeutical Medical Inc. pitch deck: common questions

What does PreveCeutical Medical Inc. do?

PreveCeutical Medical Inc. is a Canadian health sciences company that develops options for preventive and curative therapies using organic and nature‑identical products, and also engages in licensing, branding, and marketing of nutraceutical and wellness products.

Where is PreveCeutical Medical Inc. based?

The pitch deck describes PreveCeutical as incorporated in British Columbia, Canada, with a principal address in West Vancouver, and later filings and profiles list headquarters addresses in West Vancouver and Vancouver, British Columbia.

What fundraising or listing was this pitch deck used for?

The Slideshare description notes that the pitch deck was prepared by Concord Business Plans "before they go public on the TSXv exchange," indicating it was used to support a pre‑public / going‑public financing and listing process rather than a traditional named venture round.

How much money did PreveCeutical raise with this pitch deck?

PreveCeutical later became a publicly traded company, with profiles and stock information available on exchanges and financial data platforms, but the specific amount raised in the pre‑public financing associated with this deck is not disclosed in the publicly accessible sources reviewed.

What products or programs does PreveCeutical focus on?

The deck and subsequent company descriptions indicate that PreveCeutical focuses on preventive health and wellness products, and over time has developed programs including cannabinoid Sol‑Gel nose‑to‑brain delivery, non‑addictive analgesic peptides, dual gene therapy for diabetes and obesity, and other nature‑identical peptide programs.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

Preveceutical Medical Inc. pitch deck slides

Preveceutical Medical Inc. pitch deck slide 1 of 23 — Preveceutical Medical Inc. pitch deck — slide 1 of 23

Preveceutical Medical Inc. pitch deck slide 2 of 23 — Preveceutical Medical Inc. pitch deck — slide 2 of 23

Preveceutical Medical Inc. pitch deck slide 3 of 23 — Preveceutical Medical Inc. pitch deck — slide 3 of 23

Preveceutical Medical Inc. pitch deck slide 4 of 23 — Preveceutical Medical Inc. pitch deck — slide 4 of 23

Preveceutical Medical Inc. pitch deck slide 5 of 23 — Preveceutical Medical Inc. pitch deck — slide 5 of 23

Preveceutical Medical Inc. pitch deck slide 6 of 23 — Preveceutical Medical Inc. pitch deck — slide 6 of 23

What each slide of the Preveceutical Medical Inc. pitch deck says

Slide 2

This presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Forward-looking statements and information are often, but not always, identified by the use of words such as "appear", "seek", "anticipate", "plan", "continue", "estimate", "approximate, "expect", "may", “will", "project", "predict", "potential", "targeting", "intend", could", "might", "should", "believe", "would" and similar expressions. Forward-looking statements and information are provi…

Slide 3

ll Introduction to Preveceutical “Prevention is better than cure." ~ Desiderius Erasmus Preveceutical specializes in branding a signature portfolio of disease preventive health products and services globally.

Slide 5

Preventive care both prevents disease and provides early detection. . a8 ; y ! § Wellness products £ ¢ » are the economy’s . next trillion-dollar industry.